Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Etrolizumab AI vs PFS-NSD in Healthy Subjects
NCT02996019Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2016
- Primary completion
- Apr 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Etrolizumab in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve from Hour 0 to Last Measurable Concentration and 2 more. Started Dec 2016; status: completed.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02996019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996019.